Rapamycin as a potent and selective inhibitor of vascular endothelial growth factor receptor in breast carcinoma
W. F. Wan Abdul rahman, M. S. Muhammad Sakri, T. A. D. A.-A. Tengku Din, H. Jaafar, V. Gopalan
This study evaluates rapamycin and platelet factor-4 on rat breast carcinoma, finding rapamycin effectively downregulates Flt-4 while platelet factor-4 shows limited anti-angiogenic effects.
bioRxiv · Aug 27, 2020Pathology